Research thatreshaped strategy.
Selected engagements from our Private Equity and Healthcare & Life Sciences practices.
Would a regional accounting firm's recurring revenue survive a change of ownership, and how far can fees rise before clients leave?
After years of share loss to pouches, rigid plastics, cartons, and glass, is the movement of food out of metal cans accelerating, stabilizing, or effectively complete?
What does the US market spend on measurement and process equipment, and how do buyers actually award fabrication projects?
Would the incumbent specialty retailer's own customers actually move to a challenger paint-store concept, and on what terms?
How fast will a newly launched inhaled therapy take share from a two-format incumbent, and how much of a written script becomes paid, recurring revenue?
Is a service-led distributor gaining or losing ground with the buyers who decide, and how exposed is it to direct-from-manufacturer buying?
As customers adopt AI across research and development workflows, does demand for physical consumables and analytical instruments grow, hold, or quietly erode?
How much unmet need do patients still carry in a market clinicians describe as well-served, and which treatment attributes actually move their choice of therapy?
Where is a global CRO's brand earned, where is it exposed, and does the answer change across buyer segments and functions?
Could a fragmented laboratory consumables category be sized at the instrument-category level, precisely enough to underwrite a market-entry decision?
Two candidate brand identities, four markets, two audiences: which version carries the company's mission, and does the same content even read the same way in every market?
Would a savings-realization story and three solution concepts carry an upcoming campaign, tested blind with the exact committee it targets?